Dual-hormone artificial pancreas is a step closer for patients with Type 1 diabetes

January 28, 2013

For patients with type 1 diabetes, a dual-hormone artificial pancreas system (also known as a closed-loop delivery system) improved the control of glucose levels and reduced the risk of hypoglycemia compared with conventional pump treatment in a trial published in CMAJ (Canadian Medical Association Journal).

It is challenging for patients with to control their glucose levels because tight glucose control increases the incidence of hypoglycemia (dangerously low glucose levels). Insulin pump treatment, which provides a continuous predetermined subcutaneous supply of insulin, is available, but hypoglycemia still occurs.

"Hypoglycemia is feared by most patients and remains the most common adverse effect of ," writes Ahmad Haidar, Institut de Recherches Cliniques de Montréal and McGill University, with coauthors.

The dual-hormone delivers insulin and glucagon using infusion pumps based on continuous glucose sensor readings as guided by an intelligent dosing algorithm. The infusion pumps and the are already on the market, but the intelligent algorithm was developed by the researchers in Montreal.

Researchers sought to assess the ability of the artificial pancreas to improve glucose control and reduce the possibility of hypoglycemia in adults with type 1 diabetes. They conducted a trial with 15 adult patients who had been using an for at least 3 months. Patients were admitted to a clinical research facility for 2 15-hour experiments, and their glucose levels were controlled in 1 visit using the artificial pancreas system and the other visit using conventional pump treatment. On each visit, the patients exercised on a stationary bike, received an evening meal and a bedtime snack, and stayed in the facility until the next morning.

With the artificial pancreas system, participants' glucose levels were in the target zone 71% of the time compared to 57% with the conventional pump treatment. The artificial pancreas resulted in a 20-fold reduction in the number of night-time glucose measurements in the low glucose level range.

"[The dual-hormone artificial pancreas] improved glucose control and reduced the risk of hypoglycemia in our 15 participants, as compared with continuous subcutaneous insulin infusion," write the authors. "Rates of hypoglycemia were reduced, with no increased risk of hyperglycemia."

"Closed-loop delivery systems have the potential to substantially improve the management of diabetes and the safety of patients. These systems will probably be introduced gradually to clinical practice, with early generations focusing on overnight and using insulin alone," conclude the authors.

In a related commentary, Drs. David Nathan and Steven Russell, Massachusetts General Hospital, Harvard Medical School, write "Although [this] study is neither the first nor the longest investigation using a dual-hormone artificial pancreas, it is the first to compare such an apparatus to conventional intensive therapy in a randomized design. Treatment with the artificial pancreas increased the amount of time spent in the target range of blood glucose levels and decreased hypoglycemia. Thus, Haidar and colleagues show that low doses of glucagon administered under the control of a computer algorithm can act as a counter-regulatory hormone, preventing from falling too low."

Explore further: Automatic suspension of insulin delivery via insulin pumps reduces hypoglycemia

More information: Research paper: www.cmaj.ca/lookup/doi/10.1503/cmaj.121265
Commentary: www.cmaj.ca/lookup/doi/10.1503/cmaj.130011

Related Stories

Automatic suspension of insulin delivery via insulin pumps reduces hypoglycemia

February 9, 2012
An automated on/off feature built into insulin pump systems can suspend insulin delivery when it detects low blood glucose levels (via continuous glucose monitoring), significantly reducing the severity and duration of hypoglycemia ...

Artificial pancreas may improve overnight control of diabetes in adults

April 15, 2011
Two small randomised trials published in the British Medical Journal today suggest that closed loop insulin delivery (also known as an artificial pancreas) may improve overnight blood glucose control and reduce the risk of ...

ADA: Hypo-hyperglycemia minimizer system feasible

June 12, 2012
(HealthDay) -- The hypoglycemia-hyperglycemia minimizer (HHM) system, which includes a continuous, subcutaneous insulin infusion pump, continuous glucose monitor (CGM), and software, is able to predict changes in blood glucose ...

Liquid glucagon formulation discovered for potential use in artificial pancreas systems

June 12, 2012
Researchers at Oregon Health & Science University (OHSU) and Legacy Health have discovered a liquid glucagon formulation that may be useable in standard diabetes pumps. Such a formulation could broaden the use of glucagon ...

Recommended for you

Diabetes or its precursor affects 100 million Americans

July 19, 2017
Almost one-third of the US population—100 million people—either has diabetes or its precursor condition, known as pre-diabetes, said a government report Tuesday.

One virus may protect against type 1 diabetes, others may increase risk

July 11, 2017
Doctors can't predict who will develop type 1 diabetes, a chronic autoimmune disease in which the immune system destroys the cells needed to control blood-sugar levels, requiring daily insulin injections and continual monitoring.

Diabetes complications are a risk factor for repeat hospitalizations, study shows

July 7, 2017
For patients with diabetes, one reason for hospitalization and unplanned hospital readmission is severe dysglycemia (uncontrolled hyperglycemia - high blood sugar, or hypoglycemia - low blood sugar), says new research published ...

Researchers identify promising target to protect bone in patients with diabetes

July 7, 2017
Utilizing metabolomics research techniques, NYU Dentistry researchers investigated the underlying biochemical activity and signaling within the bone marrow of hyperglycemic mice with hopes of reducing fracture risks of diabetics

Immune system killer cells increase risk of diabetes

July 6, 2017
More than half of the German population is obese. One effect of obesity is to chronically activate the immune system, placing it under continuous stress. Researchers in Jens Brüning's team at the Max-Planck-Institute for ...

Repurposed asthma drug shows blood sugar improvement among some diabetics

July 5, 2017
After 12 weeks of taking an anti-asthma drug, a subset of patients with type 2 diabetes showed a clinically significant reduction in blood glucose during a randomized, double blind, placebo-controlled clinical trial, report ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.